Telomir Pharmaceuticals Inc (NASDAQ:TELO) shares, rose in value on Wednesday, June 18, with the stock price down by -5.38% to the previous day’s close as strong demand from buyers drove the stock to $1.76.
Actively observing the price movement in the last trading, the stock closed the session at $1.86, falling within a range of $1.705 and $1.92. Referring to stock’s 52-week performance, its high was $8.40, and the low was $1.85. On the whole, TELO has fluctuated by -30.71% over the past month.
With the market capitalization of Telomir Pharmaceuticals Inc currently standing at about $52.38 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TELO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of TELO currently trading nearly -13.38% and -25.06% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 33.97, while the 7-day volatility ratio is showing 4.10% which for the 30-day chart, stands at 4.87%. Furthermore, Telomir Pharmaceuticals Inc (TELO)’s beta value is -0.39, and its average true range (ATR) is 0.21.
A comparison of Telomir Pharmaceuticals Inc (TELO) with its peers suggests the former has fared considerably weaker in the market. TELO showed an intraday change of -5.38% in last session, and over the past year, it shrunk by -68.00%%.
Data on historical trading for Telomir Pharmaceuticals Inc (NASDAQ:TELO) indicates that the trading volumes over the past 10 days have averaged 0.36 and over the past 3 months, they’ve averaged 199.55K. According to company’s latest data on outstanding shares, there are 29.76 million shares outstanding.
Nearly 42.03% of Telomir Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 12.39% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.29 million shares as on 2025-05-30, resulting in a short ratio of 15.8. According to the data, the short interest in Telomir Pharmaceuticals Inc (TELO) stood at 1171.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 2.23 million. The stock has fallen by -57.28% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TELO stock heading into the next quarter.
